Two Stable Peptide Tracers Could Image and Treat Cancer Using the Same Target
Two gallium-68-labeled peptides showed high tumor uptake and clear PET imaging in prostate cancer mouse models, supporting their use as diagnostic partners to radiation therapy versions.
Quick Facts
What This Study Found
Two metabolically stable peptides targeting the gastrin-releasing peptide receptor (GRPR) — [68Ga]Ga-PKB2 and [68Ga]Ga-PKB3 — were successfully labeled with gallium-68 for PET imaging. Both showed high tumor uptake in prostate cancer xenografts (16 ± 3%IA/g and 17 ± 2%IA/g, respectively), fast blood clearance below 0.5%IA/g at 2 hours, and low nanomolar receptor affinity.
[68Ga]Ga-PKB3 showed significantly higher uptake in GRPR-expressing pancreas tissue and lower kidney uptake than PKB2, suggesting a potentially better safety profile. PET/CT images clearly delineated tumors, and both tracers are proposed as diagnostic counterparts to their lutetium-177-labeled therapy versions, forming a theranostic pair.
Key Numbers
n=PC-3 xenograft mice · Tumor uptake: 16 ± 3%IA/g (PKB2), 17 ± 2%IA/g (PKB3) · IC50: low nanomolar · Radiochemical yield >99% · Radiochemical purity >97% · Blood clearance <0.5%IA/g at 2h
How They Did This
Researchers labeled two previously developed GRPR-targeting peptides (PKB2 with DOTAGA chelator, PKB3 with DOTA chelator) with gallium-68. They tested receptor affinity and cell uptake in PC-3 prostate cancer cells, then evaluated biodistribution and PET/CT imaging in mice bearing PC-3 tumor xenografts.
Why This Research Matters
GRPR is overexpressed in several cancers including prostate, breast, and pancreatic cancer. Having matched diagnostic and therapeutic peptide pairs — one for imaging with PET, one for targeted radiation therapy — could let doctors first locate tumors precisely and then treat them with the same targeting molecule. This study advances the concept of peptide-based theranostics where the same receptor-binding peptide serves both diagnostic and therapeutic purposes.
The Bigger Picture
Peptide-based theranostics — using the same targeting molecule for both imaging and therapy — is a rapidly growing approach in nuclear medicine. GRPR-targeting adds to the success seen with somatostatin receptor theranostics (like Lutathera). Developing matched gallium-68/lutetium-177 pairs could expand precision oncology to more cancer types.
What This Study Doesn't Tell Us
This is a preclinical animal study only — no human data exists yet. The mouse xenograft model may not perfectly reflect how these tracers behave in human tumors. Long-term toxicity and repeated dosing were not assessed. Translation to clinical use will require Phase I safety trials.
Questions This Raises
- ?Will these tracers perform as well in human patients as they do in mouse models?
- ?Could PKB3's lower kidney uptake translate into fewer side effects during repeated therapeutic dosing?
- ?How do these GRPR-targeting tracers compare to existing bombesin-based imaging agents in clinical development?
Trust & Context
- Key Stat:
- 16–17%IA/g tumor uptake Both peptide tracers concentrated heavily in prostate tumors while clearing rapidly from blood
- Evidence Grade:
- This is a preclinical animal study using mouse xenograft models. While results are promising, no human data has been generated yet, placing this at a preliminary evidence level.
- Study Age:
- Published in 2026, this is current research representing the latest developments in GRPR-targeted PET imaging peptides.
- Original Title:
- Exploring the theranostic potential of two metabolically stable GRPR-targeting peptides labelled with Ga-68 for PET imaging.
- Published In:
- EJNMMI radiopharmacy and chemistry, 11(1) (2026)
- Authors:
- Obeid, Karim, Bezverkhniaia, Ekaterina, Tolmachev, Vladimir, Orlova, Anna, Kanellopoulos, Panagiotis
- Database ID:
- RPEP-15819
Evidence Hierarchy
Frequently Asked Questions
What is a theranostic peptide pair?
A theranostic pair uses the same tumor-targeting peptide labeled with two different radioactive atoms — one for diagnostic imaging (like gallium-68 for PET scans) and one for treatment (like lutetium-177 for radiation therapy). This lets doctors first see where the cancer is, then treat it with targeted radiation.
What is GRPR and why target it in cancer?
GRPR (gastrin-releasing peptide receptor) is a protein found in high amounts on certain cancer cells, especially prostate, breast, and pancreatic cancers. By designing peptides that specifically bind GRPR, researchers can deliver imaging agents or therapeutic radiation directly to the tumor while sparing healthy tissue.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15819APA
Obeid, Karim; Bezverkhniaia, Ekaterina; Tolmachev, Vladimir; Orlova, Anna; Kanellopoulos, Panagiotis. (2026). Exploring the theranostic potential of two metabolically stable GRPR-targeting peptides labelled with Ga-68 for PET imaging.. EJNMMI radiopharmacy and chemistry, 11(1). https://doi.org/10.1186/s41181-026-00431-5
MLA
Obeid, Karim, et al. "Exploring the theranostic potential of two metabolically stable GRPR-targeting peptides labelled with Ga-68 for PET imaging.." EJNMMI radiopharmacy and chemistry, 2026. https://doi.org/10.1186/s41181-026-00431-5
RethinkPeptides
RethinkPeptides Research Database. "Exploring the theranostic potential of two metabolically sta..." RPEP-15819. Retrieved from https://rethinkpeptides.com/research/obeid-2026-exploring-the-theranostic-potential
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.